LAMICTAL XR (lamotrigine) by GSK is organic cation transporter 2 inhibitors [moa]. Approved for anti-epileptic agent [epc]. First approved in 2009.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
LAMICTAL XR is an extended-release oral tablet formulation of lamotrigine, a small-molecule anti-epileptic agent approved by FDA in May 2009. It works primarily through inhibition of organic cation transporter 2, which modulates neuronal excitability and seizure threshold. The product is indicated for anti-epileptic use and represents a sustained-release alternative to immediate-release lamotrigine formulations in the epilepsy treatment landscape.
Organic Cation Transporter 2 Inhibitors
Anti-epileptic Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine
A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults
Worked on LAMICTAL XR at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
LAMICTAL XR supports roles in brand management, medical science liaison (MSL) positions focused on neurologist engagement, field sales teams, and regulatory affairs specialists managing patent expiry transitions. Critical skills include anti-epileptic therapy knowledge, managed care negotiation experience, and generic transition management. Currently zero open positions are linked to this product profile.